Streptozotocin Based Chemotherapy in Advanced G2 Pancreatic Neuroendocrine Tumors (PNET): Efficacy According to KI67 Index

#1116

Introduction: Streptozotocin (STZ) with fluorouracil (FU) or doxorubicin (DOX) is approved in well differentiated advanced pancreatic neuroendocrine tumors (PNET).

Aim(s): To evaluate the efficacy of STZ-FU and STZ-DOX in patients with grade 2 stage IV PNET according to Ki-67.

Materials and methods: We present a subset analysis from the RGETNE (registry of Spanish NET Group (GETNE)). Forty-five patients were recruited at a single Spanish centre from 2004-2012. Patients with Ki67 3-10% received STZ-FU while those with Ki-67 11-19% received STZ-DOX until progression. Response was evaluated according to RECIST v1.1 criteria every 3 months.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Jimenez-Fonseca P

Authors: Jiménez-Fonseca P, Carmona-Bayonas A, Solís M, Vieitez J, Sanchez M,

Keywords: chemotherapy, streptozotocin, fluorouracil, PNET, Ki67,